ARCHIVES

Guest Editorial: The Walue of Quality of Life Data In Judging Patient Benefit: experts Respond To ODAC

This article is from The Cancer Letter archive.

Vol. 25 No. 33 | September 3, 1999

Download PDF Visit The Full Archive

Related Articles

Gleevec Approved For Pediatric CML

May 23, 2003

Grants Funding: R01 Payline To tighten To 22nd Percentile This Year, NCI Says.

November 29, 1996

FDA Hazleton Probe Finds Some Problems; Results Unaffected

April 23, 1976

CCIRC Reviews Two Existing, One Prospective Cooperative Group

March 4, 1977

Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards

February 7, 1997

UT System Chancellor to Travel to MD Anderson After Faculty Senate Survey Finds Plunging Morale

September 6, 2013